Mpox vaccine and infection-driven human immune signatures

Mpox, formerly known as monkeypox, outbreaks outside endemic areas peaked in July 2022, infecting more than 85,000 people and raising concerns about our preparedness against this emerging viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side effects than previous smallpox vaccines and demonstrated efficacy against mpox infection in humans. Comparing JYNNEOS vaccine and mpox induced immunity is imperative to evaluate the immunogenicity of JYNNEOS and inform vaccine administration and design.